Pasithea Therapeutics (KTTA) Gains from Investment Securities (2021 - 2025)
Pasithea Therapeutics (KTTA) posted Gains from Investment Securities of -$46870.0 for Q3 2025, down 655.6% sequentially from $8436.0 in Q2 2025, and down 166.67% YoY from $70306.0 in Q3 2024.
Pasithea Therapeutics (KTTA) Gains from Investment Securities (2021 - 2025) Analysis & Trends
Pasithea Therapeutics has reported Gains from Investment Securities for 5 years, with the latest figure at -$46870.0 in Q3 2025.
- Quarterly Gains from Investment Securities fell 166.67% year-over-year to -$46870.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$115301.0 (down 248.19% YoY) and the FY2025 annual result came in at -$115301.0, down 248.19% from the prior year.
- Gains from Investment Securities retreated to -$46870.0 in Q3 2025 per KTTA's latest filing, from $8436.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $335317.0 in Q3 2022 and troughed at -$2.6 million in Q4 2021.
- A 5-year average of -$218439.5 and a median of -$14061.0 in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities soared 256.25% in 2024, then sank 187.72% in 2025.
- Over 5 years, Gains from Investment Securities stood at -$2.6 million in 2021, then soared by 62.09% to -$980509.0 in 2022, then soared by 105.64% to $55307.0 in 2023, then tumbled by 102.54% to -$1406.0 in 2024, then sank by 3233.57% to -$46870.0 in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$46870.0, $8436.0, and -$76867.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -46,870.00 |
| Sep 30, 2025 | -46,870.00 |
| Jun 30, 2025 | 8,436.00 |
| Jun 30, 2025 | 8,436.00 |
| Mar 31, 2025 | -76,867.00 |
| Mar 31, 2025 | -76,867.00 |
| Dec 31, 2024 | -1,406.00 |
| Dec 31, 2024 | -1,406.00 |
| Sep 30, 2024 | 70,306.00 |
| Sep 30, 2024 | 70,306.00 |
| Jun 30, 2024 | 35,622.00 |
| Jun 30, 2024 | 35,622.00 |
| Mar 31, 2024 | -26,716.00 |
| Mar 31, 2024 | -26,716.00 |
| Dec 31, 2023 | 55,307.00 |
| Dec 31, 2023 | 55,307.00 |
| Sep 30, 2023 | -44,996.00 |
| Sep 30, 2023 | -44,996.00 |
| Jun 30, 2023 | -113,426.00 |
| Jun 30, 2023 | -113,426.00 |